

# Suven gets three product patents in 3 countries

TRUSHNA UDGIRKAR

Hyderabad

SUVEN Life sciences on Monday said it has expanded its drug discovery portfolio to new therapeutic areas such as Major Depressive Disorder (MDD), obesity and pain through neuronal nicotinic receptor modulators.

Under this, the company has been granted one product patent from Australia, one from South Korea and one from China corresponding to the New Chemical Entities. The treatment of the disorders is associated with neurodegenerative diseases and these patents are valid until 2029 and 2030.

"The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD). With these new patents, Suven has a total of seventeen granted patents from Australia, thirteen from South Korea and thirteen product patents from China," the company said in a statement.

At a later time it also intends to out-license the products out of these inventions at various phases of clinical development like at Phase-I or Phase-II.

With these new patents, Suven now has 17 granted product patents from Australia, 13 from South Korea and 13 from China.

Suven Life's scrip is currently trading at Rs 86.50 on the BSE, up 3.78 per cent, over the previous close of Rs 83.35.

Suven Life Sciences, in



## Expansion plans

- Firm granted one product patent from Australia, one from South Korea and from china
- The treatment of the disorders is associated with neurodegenerative diseases
- It also intends to out-license the products out of these inventions

the business of design, manufacture and supply of Bulk Active, Drug Intermediates and; Fine Chemicals, catering to the needs of global Life Science Industry, is committed to provide customers with products fulfilling customer's needs and expectations.

Suven Life Sciences' net profit galloped 369.5 per cent to Rs 36.43 crore on 91.4 per cent growth in net sales to Rs 119.43 crore in Q3 December 2013 over Q3 December 2012.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products. The company has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development.

trushnaudgirkar  
@mydigitalfc.com

Patent